⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 1, 2024Open Access

Supplementary Figure S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure S1. Innate immune responses at baseline vs 2-3 cycles of BTKi.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Teglgaard et al. (2024) studied this question.

synapsesocial.com/papers/68e6c4b3b6db643587643603 https://doi.org/10.1158/1078-0432.25728709.v1

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials2024
2Supplementary Figure S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials2024
3Supplementary Figure S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials2024
4Supplementary Figure S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials2024
5Supplementary Figure S4 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials2024